| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S00467-020-04476-9 |
| P698 | PubMed publication ID | 32086590 |
| P50 | author | Jun Oh | Q87932568 |
| P2093 | author name string | Jae Il Shin | |
| Jiwon M Lee | |||
| Andreas Kronbichler | |||
| P2860 | cites work | Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome | Q93061841 |
| Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial | Q93160871 | ||
| Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial | Q93374500 | ||
| Mutations in EMP2 cause childhood-onset nephrotic syndrome | Q24297429 | ||
| Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible | Q24312154 | ||
| COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness | Q24606103 | ||
| Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis | Q30541740 | ||
| Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome | Q33387197 | ||
| Rituximab for nephrotic syndrome in children. | Q33555088 | ||
| Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group | Q33584368 | ||
| The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. | Q33943247 | ||
| Rituximab therapy in idiopathic membranous nephropathy: a 2-year study | Q34362660 | ||
| Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome | Q34405386 | ||
| Enalapril dosage in steroid-resistant nephrotic syndrome | Q34543588 | ||
| The mechanism of action of methylprednisolone in the treatment of multiple sclerosis | Q34559491 | ||
| COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement | Q34687106 | ||
| Effect of cyclosporin A on proteinuria in the course of glomerulopathy associated with WT1 mutations | Q34746123 | ||
| Nephrotic syndrome in childhood. | Q35207868 | ||
| Treatment of steroid and cyclosporine-resistant idiopathic nephrotic syndrome in children. | Q35226744 | ||
| A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis | Q35669295 | ||
| Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group | Q35704498 | ||
| KANK deficiency leads to podocyte dysfunction and nephrotic syndrome | Q35836132 | ||
| Clinical trial of focal segmental glomerulosclerosis in children and young adults | Q35837532 | ||
| Rituximab in children with resistant idiopathic nephrotic syndrome | Q35982341 | ||
| Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome | Q36153584 | ||
| Evidence-based management of steroid-sensitive nephrotic syndrome | Q36169458 | ||
| Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid-Resistant Nephrotic Syndrome | Q36543103 | ||
| Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome | Q37202763 | ||
| Thirteen novel NPHS1 mutations in a large cohort of children with congenital nephrotic syndrome | Q37289211 | ||
| Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie | Q37315097 | ||
| Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. | Q37359035 | ||
| ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption | Q37384113 | ||
| Abatacept in B7-1-positive proteinuric kidney disease | Q37633142 | ||
| Recent advances in understanding and treating nephrotic syndrome | Q37635783 | ||
| Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH). | Q37923991 | ||
| Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. | Q38050959 | ||
| Second-line immunosuppressive treatment of childhood nephrotic syndrome: a single-center experience | Q38191615 | ||
| Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. | Q38236140 | ||
| Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency | Q38236847 | ||
| Focal segmental glomerulosclerosis and medullary nephrocalcinosis in children with ADCK4 mutations. | Q38403821 | ||
| The incidence of the nephrotic syndrome in childhood in Germany | Q38712759 | ||
| Interventions for idiopathic steroid-resistant nephrotic syndrome in children. | Q38801673 | ||
| Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment | Q38854254 | ||
| Targeting mTOR Signaling Can Prevent the Progression of FSGS. | Q38922365 | ||
| Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology | Q38991259 | ||
| Rituximab for immunologic renal disease: What the nephrologist needs to know | Q39245887 | ||
| Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome | Q39398182 | ||
| Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. | Q39440837 | ||
| Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras | Q39680835 | ||
| Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome | Q39712811 | ||
| Nephrotic syndrome in infants and children: pathophysiology and management | Q40039238 | ||
| Direct effects of dexamethasone on human podocytes | Q40256235 | ||
| Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic? | Q40486811 | ||
| Long-term outcome of idiopathic steroid-resistant nephrotic syndrome in children | Q40579169 | ||
| High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan (JP-SHINE study). | Q40596186 | ||
| Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome | Q40711347 | ||
| Response to cyclosporine in steroid-resistant nephrotic syndrome: discontinuation is possible | Q41027140 | ||
| Mesenchymal Stem Cells May Ameliorate Nephrotic Syndrome Post-Allogeneic Hematopoietic Stem Cell Transplantation-Case Report | Q41417888 | ||
| Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study. | Q41467613 | ||
| Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up | Q42278929 | ||
| Unsuccessful Treatment with Abatacept in Recurrent Focal Segmental Glomerulosclerosis after Kidney Transplantation | Q42322601 | ||
| B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS. | Q42371173 | ||
| Clinical and genetic heterogeneity in familial steroid-sensitive nephrotic syndrome | Q42698311 | ||
| Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: a systematic review and network meta-analysis | Q42700702 | ||
| Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome | Q43232395 | ||
| Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome | Q43461510 | ||
| A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children | Q43588188 | ||
| Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome | Q44407315 | ||
| Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis. | Q44680239 | ||
| Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile | Q44899008 | ||
| Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome | Q45025843 | ||
| Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome | Q45230134 | ||
| Switch from cyclosporine A to mycophenolate mofetil in nephrotic children | Q45272404 | ||
| FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy | Q45757311 | ||
| Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation. | Q45983340 | ||
| Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases | Q46079811 | ||
| Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study | Q46091412 | ||
| Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial | Q46096920 | ||
| Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade? | Q46291457 | ||
| A novel multidrug therapy for difficult cyclosporine-resistant focal segmental glomerulosclerosis. | Q46299037 | ||
| Ofatumumab in post-transplantation recurrence of a pediatric steroid-resistant idiopathic nephrotic syndrome. | Q52640874 | ||
| Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children. | Q52838570 | ||
| Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. | Q52846398 | ||
| Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome. | Q52935578 | ||
| Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. | Q53365410 | ||
| Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome. | Q53421441 | ||
| Levamisole treatment in steroid-sensitive and steroid-resistant nephrotic syndrome. | Q54124424 | ||
| Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. | Q54306616 | ||
| Treatment of childhood prednisone-resistant nephrotic syndrome and focal segmental glomerulosclerosis with intravenous methylprednisolone and oral alkylating agents. | Q54414448 | ||
| Idiopathic nephrotic syndrome in children | Q57176874 | ||
| Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy | Q57180380 | ||
| Sirolimus Therapy of Focal Segmental Glomerulosclerosis Is Associated With Nephrotoxicity | Q57691291 | ||
| The role of B7-1 in proteinuria of glomerular origin | Q57701121 | ||
| Management of steroid-resistant nephrotic syndrome in children and adolescents | Q57813728 | ||
| DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS | Q58557086 | ||
| The protective effects of rapamycin on cell autophagy in the renal tissues of rats with diabetic nephropathy via mTOR-S6K1-LC3II signaling pathway | Q58751244 | ||
| Clinical course & management of childhood nephrotic syndrome in Germany: a large epidemiological ESPED study | Q61797780 | ||
| Nephrotic Syndrome in South African Children: Changing Perspectives in the New Millennium | Q64226526 | ||
| Efficacy of Mycophenolate Mofetil as a Remission Maintaining Agent in Idiopathic Childhood Nephrotic Syndrome | Q64242663 | ||
| Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook | Q73402037 | ||
| Long-term clinical and pathological effects of cyclosporin in children with nephrosis | Q73639741 | ||
| A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome | Q79331373 | ||
| Mycophenolate mofetil therapy for children with intractable nephrotic syndrome | Q80110616 | ||
| Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study | Q80535367 | ||
| Rituximab in patients with the steroid-resistant nephrotic syndrome | Q80538441 | ||
| A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis | Q80796893 | ||
| Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency | Q81523690 | ||
| Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome | Q83406637 | ||
| Use of sirolimus in patients with primary steroid-resistant nephrotic syndrome | Q83904705 | ||
| Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome | Q83989262 | ||
| Partial remission of resistant nephrotic syndrome after oral galactose therapy | Q84220872 | ||
| Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome in children | Q84971281 | ||
| Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol | Q85317930 | ||
| Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome | Q87240772 | ||
| Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome | Q87423069 | ||
| Ofatumumab for rituximab-resistant nephrotic syndrome | Q87522692 | ||
| Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome | Q87572233 | ||
| Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome | Q89321513 | ||
| Infrequent tacrolimus-induced nephrotoxicity in French patients with steroid-dependent nephrotic syndrome | Q90084496 | ||
| Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children | Q90626029 | ||
| Exploring the Clinical and Genetic Spectrum of Steroid Resistant Nephrotic Syndrome: The PodoNet Registry | Q90677029 | ||
| Levamisole for children with nephrotic syndrome: new evidence for the use of an "old" drug | Q90868585 | ||
| Molecular stratification of idiopathic nephrotic syndrome | Q90951107 | ||
| Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin | Q91057275 | ||
| Cyclophosphamide versus cyclosporine A therapy in steroid-resistant nephrotic syndrome: a retrospective study with a mean 5-year follow-up | Q91301517 | ||
| Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence? | Q91591677 | ||
| High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy | Q92152561 | ||
| Rituximab for Children With Difficult-to-Treat Nephrotic Syndrome: Its Effects on Disease Progression and Growth | Q92652725 | ||
| Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET). | Q46399341 | ||
| Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents | Q46519718 | ||
| Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity | Q46566229 | ||
| Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis | Q46694715 | ||
| A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis | Q47155702 | ||
| Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome | Q47417726 | ||
| Whole Exome Sequencing of Patients with Steroid-Resistant Nephrotic Syndrome | Q47615276 | ||
| Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. | Q47997703 | ||
| Further phenotypic heterogeneity of CoQ10 deficiency associated with steroid resistant nephrotic syndrome and novel COQ2 and COQ6 variants | Q48101924 | ||
| Single infusion of low-dose ofatumumab in a child with complicated nephrotic syndrome with anti-rituximab antibodies. | Q48106783 | ||
| Ofatumumab for the treatment of childhood nephrotic syndrome. | Q48221532 | ||
| A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome | Q48570174 | ||
| Steroid-resistant nephrotic syndrome: past and current perspectives | Q49500608 | ||
| Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. | Q50047399 | ||
| Trends and Characteristics of US Medicare Spending on Repository Corticotropin | Q50155309 | ||
| Efficacy and Safety of Cyclosporine versus Tacrolimus in Steroid and Cyclophosphamide Resistant Nephrotic Syndrome: A Prospective Study. | Q50417540 | ||
| Predictive factors for ciclosporin-associated nephrotoxicity in children with minimal change nephrotic syndrome. | Q51486296 | ||
| TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. | Q51637426 | ||
| Application of next-generation sequencing technology to diagnosis and treatment of focal segmental glomerulosclerosis. | Q52561530 | ||
| P921 | main subject | nephrotic syndrome | Q504790 |
| P577 | publication date | 2020-02-21 | |
| P1433 | published in | Pediatric Nephrology | Q15749796 |
| P1476 | title | Current understandings in treating children with steroid-resistant nephrotic syndrome |
Search more.